# PTGX PDUFA Calendar: FDA Decision Dates & Catalyst Timeline

Canonical URL: https://biopharmsignal.com/pdufa-calendar/PTGX
Company: Protagonist Therapeutics Inc

BioPharmSignal tracks active PDUFA and FDA decision milestones associated with PTGX.

## PTGX PDUFA Milestones

- 2026-03-17 — FDA Approval — FDA approved application. FDA recorded approval of ICOTYDE (icotrokinra) on March 17, 2026. This list-only historical record is sourced from the official FDA...
  Company: Protagonist Therapeutics Inc
  Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220149
  Event detail: https://biopharmsignal.com/pdufa-calendar/PTGX/icotyde-icotrokinra-icotyde-nda.md
  Month page: https://biopharmsignal.com/pdufa-calendar/2026/march (March 2026)

## Related Pages

- Company page: https://biopharmsignal.com/company/PTGX
- Interactive PDUFA Calendar: https://biopharmsignal.com/pdufa-calendar

## FAQ

### What does the PTGX PDUFA calendar show?

It shows active PDUFA and FDA decision milestones associated with PTGX, including decision dates, application stage, and summary details when available.
### Where can I find more context for PTGX?

Use the BioPharmSignal company page for PTGX to read related news, stock data, sector context, and company-specific updates.
### Are these dates investment advice?

No. PDUFA dates are research inputs, not investment recommendations. Always review primary sources and understand the clinical and regulatory context.